Sichuan Dark Tea-Based Medicated Dietary Formula Improves Obesity-Induced Renal Lipid Metabolism Disorder in Mice by Remodeling Gut Microbiota and Short-Chain Fatty Acid Metabolism

To investigate the renoprotective effects of a Sichuan dark tea-based medicated dietary formula (alternatively referred to as Qing, or clarity in Chinese) on mice with diet-induced obesity (DIO) and to explore the specific mechanisms involved.  Methods  Male C57BL/6 mice were randomly assigned to three groups, a control group, a DIO group, and a Qing treatment group, or the Qing group, with 8 mice in each group. The mice in the control group were given normal maintenance feed and purified water, and the other two groups were fed a high-fat diet for 12 weeks to establish the DIO model. After that, high-fat diet continued in the DIO group, while the Qing group was given Qing at the same time for 12 weeks, during which period the weight of the mice was monitored and recorded every week. The mice were sacrificed after 12 weeks. Serum samples were collected and the levels of triglyceride (TG), total cholesterol (TC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and albumin were measured to evaluate liver function. In addition, renal lipids were extracted to determine the levels of TG and TC in the kidney and periodic acid-Schiff (PAS) and oil red O stainings were performed to evaluate kidney pathological injury. Western blot was performed to determine the phosphorylated AMPK (pAMPK)/AMPK ratio in the kidney tissue. RT-qPCR and Western blot were used to determine the expression of proteins related to fatty acid oxidation, including acetyl-CoA carboxylase 1 (ACC1), carnitine acyltransferase 1 (CTP1), peroxisome proliferators-activated receptor γ (PPARγ), peroxisome proliferators-activated receptor-1 α (PPAR1α), sterol-regulatory element binding proteins (SREBP-1), and key proteins related to lipid synthesis, including fatty acid synthase (FASN) and stearoyl-coenzyme A desaturase 1 (stearoyl-CoA desaturase) in the kidney tissue. 16SrRNA and metabolomics were applied to analyze the gut microbiota in the intestinal contents and its metabolites.  Results  Compared with those of the control group, the levels of liver mass (P=0.0003), serum ALT (P<0.0001) and AST (P=0.0001), and kidney TC (P=0.0191) and TG (P=0.0101) of the DIO group were significantly increased and there was lipid deposition in the kidney. Compared with those of the DIO group, mice in the Qing group showed effective reduction in liver mass (P=0.0316) and improvements in the abnormal serum levels of AST (P=0.0012) and ALT (P=0.0027) and kidney TC (P=0.0200) and TG (P=0.0499). In addition, mice in the Qing group showed significant improvement in lipid deposition in the kidney. Qing group showed increased pAMPK/AMPK ratio in comparison with that of the DIO group. In comparison with those of the control group, mice in the DIO group had upregulated expression of lipid synthesis-related genes and proteins (SREBP-1, FASN, and SCD1). As for the fatty acid oxidation-related genes and proteins, DIO mice showed upregulated expression of ACC1 and downregulated expression of CPT1A, PPARγ, and PGC1α in comparison with those of the control group. In the Qing goup, improvements in regard to all these changes were observed. The Qing group demonstrated improvement in the disrupted homeostasis of the gut microbiota. Short-chain fatty acids in the cecal contents, especially isovaleric acid and propionic acid, were also restored.  Conclusion  Sichuan dark tea-based medicated dietary formula may improve renal lipid metabolism by regulating gut microbiota and the levels of intestinal short-chain fatty acids, thereby protecting obesity-related kidney injury. Isovaleric acid and propionic acid may be the metabolites key to its regulation of gut microbiota.

 

Keywords: High-fat diet,  Obesity,  Renal lipid metabolism,  Chronic kidney disease, Sichuan dark tea

 

BLÜHER M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol，2019，15(5): 288–298. doi: 10.1038/s41574-019-0176-8.

CHEN Y， DABBAS W， GANGEMI A， et al. Obesity management and chronic kidney disease. Semin Nephrol，2021，41(4): 392–402. doi: 10. 1016/j.semnephrol.2021.06.010.

WEINBERG J M. Lipotoxicity. Kidney Int，2006，70(9): 1560–1566. doi: 10.1038/sj.ki.5001834.

MOUNT P， DAVIES M， CHOY S W， et al. Obesity-related chronic kidney disease--the role of lipid metabolism. Metabolites，2015，5(4): 720–732. doi: 10.3390/metabo5040720.

KANG H M， AHN S H， CHOI P， et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med，2015，21(1): 37–46. doi: 10.1038/nm.3762.

ZHANG C， ZHANG M， WANG S， et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J，2010，4(2): 232–241. doi: 10.1038/ismej.2009. 112.

WANG X， YANG S， LI S， et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut，2020， 69(12): 2131–2142. doi: 10.1136/gutjnl-2019-319766.

ZHU M Z， LI N， ZHOU F， et al. Microbial bioconversion of the chemical components in dark tea. Food Chem，2020，312: 126043. doi: 10. 1016/j.foodchem.2019.126043.

TANG G Y， MENG X， GAN R Y， et al. Health functions and related molecular mechanisms of tea components: an update review. Int J Mol Sci，2019，20(24): 6196. doi: 10.3390/ijms20246196.

HE G， CHEN T， HUANG L， et al. Tibetan tea reduces obesity brought on by a high-fat diet and modulates gut flora in mice. Food Sci Nutr， 2023，11(10): 6582–6595. doi: 10.1002/fsn3.3607.

THOMPSON P D， PANZA G， ZALESKI A， et al. Statin-associated side effects. J Am Coll Cardiol，2016，67(20): 2395–2410. doi: 10.1016/j.jacc. 2016.02.071.

LI M， ZHENG Y， DENG S， et al. Potential therapeutic effects and applications of Eucommiae Folium in secondary hypertension. J Pharm Anal，2022，12(5): 711–718. doi: 10.1016/j.jpha.2021.10.004.

ARIFIN W N， ZAHIRUDDIN W M. Sample size calculation in animal studies using resource equation approach. Malays J Med Sci，2017，24(5): 101–105. doi: 10.21315/mjms2017.24.5.11.

SHI M， GUO F， LIAO D， et al. Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy. Eur J Pharmacol，2020，887: 173570. doi: 10. 1016/j.ejphar.2020.173570.

LI Q， LIU Z， HUANG J， et al. Anti-obesity and hypolipidemic effects of Fuzhuan brick tea water extract in high-fat diet-induced obese rats. J Sci Food Agric，2013，93(6): 1310–1316. doi: 10.1002/jsfa.5887.

YUAN Y， HE J， TANG M， et al. Preventive effect of Ya'an Tibetan tea on obesity in rats fed with a hypercaloric high-fat diet revealed by gut microbiology and metabolomics studies. Food Res Int，2023，165: 112520. doi: 10.1016/j.foodres.2023.112520.

De VRIES A P， RUGGENENTI P， RUAN X Z， et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol，2014，2(5): 417–426. doi: 10.1016/s2213-8587(14) 70065-8.

SUN Y， GE X， LI X， et al. High-fat diet promotes renal injury by inducing oxidative stress and mitochondrial dysfunction. Cell Death Dis， 2020，11(10): 914. doi: 10.1038/s41419-020-03122-4.

ZAKY A， GLASTRAS S J， WONG M Y W， et al. The role of the gut microbiome in diabetes and obesity-related kidney disease. Int J Mol Sci， 2021，22(17): 9641. doi: 10.3390/ijms22179641.

HILDEBRANDT M A， HOFFMANN C， SHERRILL-MIX S A， et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology，2009，137(5): 1716–1724.e1-2. doi: 10.1053/j.gastro.2009.08.042.

GAO R， ZHU C， LI H， et al. Dysbiosis signatures of gut microbiota along the sequence from healthy, young patients to those with overweight and obesity. Obesity (Silver Spring)，2018，26(2): 351–361. doi: 10.1002/oby.22088.

Da SILVA C C， MONTEIL M A， DAVIS E M. Overweight and obesity in children are associated with an abundance of Firmicutes and reduction of Bifidobacterium in their gastrointestinal microbiota. Child Obes，2020， 16(3): 204–210. doi: 10.1089/chi.2019.0280.